drugset / Trial / NCT04241523
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Phase 2
Unknown
50 enrolled
Shanghai Zhongshan Hospital
Anhui Provincial Hospital · collabTongji Hospital · collabWest China Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable HCC and improve the long term survival.
Timeline
- Start
- 2020-01
- Primary completion
- 2021-10
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |